How much will a box of Alpelisib cost in 2025?

Alpelisib(Alpelisib)-Piqray is a selective PI3Kα inhibitor developed by Novartis. It is currently one of the important targeted therapies for patients with PIK3CA gene mutation breast cancer. This drug is mainly suitable for postmenopausal women or men, hormone receptor-positive (HR+), HER2-negative, advanced or metastatic breast cancer patients with PIK3CA mutations. Its mechanism of action is to precisely inhibit the key α subtype kinase in the PI3K pathway, thereby blocking the growth signaling of tumor cells and inhibiting abnormally active cell proliferation. In clinical practice, apelvis is usually used in combination with Fulvestrant to help delay disease progression in patients who are resistant to endocrine therapy such as aromatase inhibitors.

The drug was approved by the US FDA in 2019. It is the first PI3K inhibitor approved for PIK3CA mutated breast cancer. This approval marks a new stage in precision treatment of breast cancer. Compared with traditional endocrine therapy, Apelvis can target abnormalities at the molecular level and therefore exhibits a higher disease control rate in specific populations. With the popularization of molecular testing technology, more and more breast cancer patients are discovering PIK3CA mutations through genetic testing, giving them the opportunity to use this drug to obtain personalized treatment.

In terms of price, the original drug of Apelvis has not yet been officially launched in mainland China. Overseas markets mainly come from two sources: European version and Indian version. The European version has a specification of 150 mg and 56 tablets, and the price per box may exceed RMB 40,000. The Indian version has a specification of 150 mg and 28 tablets, and the price per box is about RMB 5,000. The price fluctuates slightly due to exchange rate changes. In addition, pharmaceutical factories in Laos and other places have launched generic versions, with 150mg*28 tablets priced at about 2,000 yuan. These generic drugs are identical in ingredients to the brand-name drugs, providing an affordable alternative for patients who cannot afford the high cost of drugs.

Reference: https://www.piqray.com/